View Risk


Article data
Damiani (2020)
Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration
10.1111/dth.13475
https://onlinelibrary.wiley.com/doi/10.1111/dth.13475

Results
Treatment
Concomitant medication (Treated with biologics vs. Not received)
COVID-19 (any condition)
Odds ratio: 3.430 (2.250-5.730) Univariate analysis

Study characteristics

Italy

Case-control study

Primary data collection

1193

1193 PsO patients treated with biologics and small molecules and we used the entire Lombardia population as controls

PsO patients: Male, N (%) 811 (68); Age, mean ± SD, years 55 ± 12.7, BMI, mean ± SD, kg/m2 28.7 ± 2.5 PsO duration, mean ± SD, years 12.3 ± 9.1 among controls 54 801 subjects were COVID-19 positive, 16 042 were self-isolated (quarantined) at home, 11796 were hospitalized, 1236 were admitted to intensive care unit (ICU), and 10 222 died.

0


Results

COVID-19 (any condition)

0

testing positive for COVID-19

Treatment

Concomitant medication

anti-PsO monotherapy (biologics or small molecules)

Not received

Treated with biologics

Odds ratio

3.430 (2.250-5.730)

No

Yes

No

none


Other information

none

Average

No

Go Back